title: A case of second renal transplantation with acute antibody-mediated rejection complicated with BK virus nephropathy.
abstract: We reported a 40-year-old female case of second renal transplantation with antibody-mediated rejection (AMR) complicated by BK virus nephropathy. She started hemodialysis (HD) at the age of 17 because of IgA nephropathy. At the age of 18, she underwent living-donor kidney transplantation from her father, but two and a half years after transplantation, she developed chronic rejection. This time, she received cadaveric renal transplantation under the negative cross-match (AHG-LCT), and HLA-AB 1 mismatch and -DR 1 mismatch. Immunosuppressive therapy was initiated using the following four immunosuppressants: methylprednisolone, mycophenolate mofetil, cyclosporine, and basiliximab. However, renal graft showed delayed function, the biopsy showed glomerulitis (g2), endarteritis (v1), and cellular infiltration (ptc3) consisting mainly of mononuclear cells in the peritubular capillary with diffusely positive C4d and anti-SV 40 large T-antigen-positive renal tubular epithelial cells on post-operative day 19. The donor-specific antibody for HLA-B46 was proven by the LAB screen method. We performed plasma exchange three times and administered immunoglobulin (15 g in total). Then, methylprednisolone pulse therapy was added, and the serum creatinine (SCr) levels gradually decreased. On post-operative day 44, the patient was removed from HD and was discharged with SCr level of 3.3 mg/dL.
authors.affiliation: Division of Nephrology, Kanazawa Medical University School of Medicine, 1-1 Daigaku, Uchinada, Kahoku, Ishikawa 920-0293, Japan. atsumi-h@kanazawa-med.ac.jp
authors.forename: Hirokatsu
authors.initials: H
authors.lastname: Atsumi
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Asaka
authors.forename: Shogo
authors.initials: S
authors.lastname: Kimura
authors.forename: Junko
authors.initials: J
authors.lastname: Imura
authors.forename: Keiji
authors.initials: K
authors.lastname: Fujimoto
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Chikazawa
authors.forename: Masaru
authors.initials: M
authors.lastname: Nakagawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Okuyama
authors.forename: Hideki
authors.initials: H
authors.lastname: Yamaya
authors.forename: Manabu
authors.initials: M
authors.lastname: Moriyama
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Tanaka
authors.forename: Koji
authors.initials: K
authors.lastname: Suzuki
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Yokoyama
mesh_terms: D000328:Adult; D001739:BK Virus / Q000472:pathogenicity*; D005260:Female; D006084:Graft Rejection / Q000276:immunology*; D015235:HLA-B Antigens / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation; D019520:Living Donors; D009395:Nephritis, Interstitial / Q000276:immunology / Q000601:surgery* / Q000821:virology; D027601:Polyomavirus Infections / Q000276:immunology / Q000601:surgery* / Q000821:virology; D012086:Reoperation; D016896:Treatment Outcome; D014412:Tumor Virus Infections / Q000276:immunology / Q000601:surgery* / Q000821:virology; D014779:Virus Replication
chemical_list: D015235:HLA-B Antigens; C080311:HLA-B46 antigen; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents